18 de octubre de 2019
  • Jueves, 17 de Octubre
  • 17 de septiembre de 2019

    Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels

    BARCELONA, Spain, Sept. 17, 2019 /PRNewswire/ -- Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA(1c) levels. Greater reductions in HbA(1c) were demonstrated with 7 mg and 14 mg oral semaglutide vs all comparators including placebo, Jardiance(®) (empagliflozin 25 mg), Januvia(®) (sitagliptin 100 mg) or Victoza(®) (liraglutide 1.8 mg). The results were presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)([1]). Oral semaglutide is an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue in a pill.

    In the analysis, data from 5,657 participants in PIONEER 1-5, 7 and 8 were grouped by trial according to baseline HbA(1c) (<=8.0%, >8.0-<=9.0% and >9.0%). The proportion of people with type 2 diabetes achieving an HbA(1c) target of <7% was greater with oral semaglutide 7 and 14 mg vs comparators in all trials and across all HbA(1c) baseline subgroups.

    "People with type 2 diabetes have individual treatment goals related to glycaemic control," said Dr Juris Meier, professor of medicine and head of the division of diabetology and GI endocrinology at the St. Josef-Hospital of the Ruhr-University of Bochum, Germany. "The findings from this analysis are particularly meaningful as they show that oral semaglutide improves glycaemic control in a wide spectrum of people with type 2 diabetes."

    The safety profile of oral semaglutide across the PIONEER programme was consistent with that of the GLP-1 receptor agonist class and similar to those seen with subcutaneous semaglutide.

    "This analysis reinforces the findings seen throughout the PIONEER trial programme, demonstrating oral semaglutide's efficacy in HbA(1c) reductions compared to commonly used type 2 diabetes treatments," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "If approved, oral semaglutide will become the first and only oral GLP-1 receptor agonist with the potential to help people with uncontrolled type 2 diabetes better manage their condition."

    About the exploratory analysis and the PIONEER clinical trial programme

    The PIONEER 1-5, 7 and 8 trials, included in this analysis, investigated oral semaglutide against diet and exercise (PIONEER 1), empagliflozin 25 mg (PIONEER 2), sitagliptin 100 mg (PIONEER 3 and 7), liraglutide 1.8 mg (PIONEER 4) and as an add-on to insulin (PIONEER 8). PIONEER 5 evaluated oral semaglutide compared to placebo in patients with moderate renal impairment.

    The PIONEER phase 3a clinical development programme for oral semaglutide was a global development programme that enrolled 9,543 people with type 2 diabetes across 10 clinical trials.

    Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com [https://www.novonordisk.com/], Facebook [http://www.facebook.com/novonordisk], Twitter [http://www.twitter.com/novonordisk], LinkedIn [http://www.linkedin.com/company/novo-nordisk], YouTube [http://www.youtube.com/novonordisk].

    References

    (1.) Meier JJ, Bauer R, Blicher TM, et al. Efficacy of oral semaglutide according to baseline HbA(1c): an exploratory subgroup analysis of the PIONEER trial programme. 55th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, September 2019.

    Further information:

    Media:Mette Kruse Danielsen: +45 3079 3883, mkd@novonordisk.com[mailto:mkd@novonordisk.com] Ken Inchausti (US): +1 609 240 9429, kiau@novonordisk.com[mailto:kiau@novonordisk.com]

    Investors:Peter Hugreffe Ankersen: +45 3075 9085, phak@novonordisk.com[mailto:phak@novonordisk.com] Valdemar Borum Svarrer: +45 3079 0301, jvls@novonordisk.com[mailto:jvls@novonordisk.com] Ann Søndermølle Rendbæk: +45 3075 2253, arnd@novonordisk.com[mailto:arnd@novonordisk.com] Kristoffer Due Berg (US): +1 609 235 2989, krdb@novonordisk.com[mailto:krdb@novonordisk.com]

    Web site: https://www.novonordisk.com/